using a luminescent atp cell viability assay, the antiproliferative effects of tce (200 microg/ml) versus all fractions were evaluated against human oral (kb, cal27), colon (ht-29, hct116, sw480, sw620), and prostate (rwpe-1, rwpe-2, 22rv1) cancer cell lines.